更新于：2024-06-24
Penehyclidine hydrochloride
盐酸戊乙奎醚
更新于：2024-06-24
概要
基本信息
原研机构 |
在研机构 |
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C20H30ClNO2 |
InChIKeyDDTVVMRZNVIVQM-UHFFFAOYSA-N |
CAS号151937-76-7 |
关联
35
项与 盐酸戊乙奎醚 相关的临床试验Effect of penehyclidine hydrochloride on postoperative nausea and vomiting in preoperative anxiety patients undergoing gynecologic outpatient surgery
Effect of penehyclidine hydrochloride on postoperative nausea and vomiting in patients undergoing thoracoscopic radical resection of lung cancer : a single-center, prospective, randomized controlled clinical trial
The effect of penehyclidine hydrochloride on postoperative pulmonary complications: A multicenter prospective randomized double-blind controlled clinical trial
100 项与 盐酸戊乙奎醚 相关的临床结果
登录后查看更多信息
100 项与 盐酸戊乙奎醚 相关的转化医学
登录后查看更多信息
100 项与 盐酸戊乙奎醚 相关的专利（医药）
登录后查看更多信息
1,447
项与 盐酸戊乙奎醚 相关的文献（医药）2024-04-01Breast cancer research and treatment
Radium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlled trials
Article
作者: Van Poznak, Catherine H ; Lee, Soo Chin ; Neven, Patrick ; Brain, Etienne ; Danielewicz, Iwona ; Li, Rui ; Wagner, Volker J ; Siegel, Jonathan M ; Coleman, Robert E ; Chik, Jeannie Y K ; Naume, Bjørn ; Rugo, Hope S ; Vega Alonso, Estela ; Uema, Deise ; Campone, Mario
Abstract:
Background:
Most women with advanced breast cancer have skeletal metastases. Radium-223 is an alpha-emitting radionuclide that selectively targets areas of bone metastases.
Methods:
Two double-blind, placebo-controlled studies of radium-223 were conducted in women with hormone receptor-positive (HR+), bone-predominant metastatic breast cancer. All patients received endocrine therapy (ET), as a single agent of the investigator’s choice (Study A) or exemestane + everolimus (Study B). Patients were randomized to receive radium-223 (55 kBq/kg) or placebo intravenously every 4 weeks for six doses. Accrual was halted following unblinded interim analyses per protocol amendments, and both studies were terminated. We report pooled analyses of symptomatic skeletal event-free survival (SSE-FS; primary endpoint), radiologic progression-free survival (rPFS) and overall survival (OS; secondary), and time to bone alkaline phosphatase (ALP) progression (exploratory).
Results:
In total, 382 patients were enrolled, and 196 SSE-FS events (70% planned total) were recorded. Hazard ratios (95% confidence intervals) and nominal p values for radium-223 + ET versus placebo + ET were: SSE-FS 0.809 (0.610–1.072), p = 0.1389; rPFS 0.956 (0.759–1.205), p = 0.7039; OS 0.889 (0.660–1.199), p = 0.4410; and time to bone ALP progression 0.593 (0.379–0.926), p = 0.0195. Radium-223- or placebo-related treatment-emergent adverse events were reported in 50.3% versus 35.1% of patients (grade 3/4: 25.7% vs. 8.5%), with fractures/bone-associated events in 23.5% versus 23.9%.
Conclusions:
In patients with HR+ bone-metastatic breast cancer, numeric differences favoring radium-223 + ET over placebo + ET for the primary SSE-FS endpoint were suggestive of efficacy, in line with the primary outcome measure used in the underlying phase 2 studies. No similar evidence of efficacy was observed for secondary progression or survival endpoints. Adverse events were more frequent with radium-223 + ET versus placebo + ET, but the safety profile of the combination was consistent with the safety profiles of the component drugs.Clinical trial registration numbersStudy A: NCT02258464, registered October 7, 2014.Study B: NCT02258451, registered October 7, 2014.
2024-03-01Asian journal of surgery
Comparison of the effectiveness and safety between endoscope-assisted and traditional open surgery in the treatment of thyroid micropapillary carcinoma: A meta-analysis
Review
作者: Wang, Xia ; Wang, Xueliang ; Bai, Junwen
Endoscopic thyroidectomy (ET), a surgical procedure widely accepted by surgeons, has been proven to be feasible. The aim of this systematic review is to evaluate the effectiveness and safety of ET compared to conventional open thyroidectomy (COT) in the treatment of papillary thyroid microcarcinoma (PTMC) through a meta-analysis. Medical literature databases, including PubMed, Embase, Cochrane Library, CBM,CNKI, Wanfang, and VIP, were systematically searched for relevant studies on ET and COT for the treatment of PTMC. The search period was from January 2000 to June 2023. Two researchers independently performed literature screening and data extraction according to the inclusion and exclusion criteria, and the Newcastle-Ottawa Scale (NOS) was used to assess the quality of the included studies. Meta-analysis was conducted using Revman 5.3 software. Six studies were eventually included, involving a total of 440 patients with PTMC. The meta-analysis results demonstrated that the ET group had shorter incision length (MD = -2.96, 95 % CI: -4.27 to -1.65, P < 0.05) and less intraoperative blood loss (MD = -18.06, 95 % CI: -32.76 to -3.37, P = 0.02 < 0.05). There was no statistically significant difference between the two groups in terms of operative time (MD = -0.83, 95 % CI: -19.64 to 17.98, P = 0.93 > 0.05), lymph node dissection (MD = 1.03, 95 % CI: -1.47 to 3.54, P = 0.42 > 0.05), postoperative hospital stay (MD = -0.96, 95 % CI: -2.00 to 0.08, P = 0.07 > 0.05), and transient recurrent laryngeal nerve paralysis (OR = 3.32, 95 % CI: 0.65 to 16.90, P = 0.15 > 0.05). Compared with COT, ET has the advantages of shorter incision length, less intraoperative blood loss, better prognosis and comparable safety, making it a worthy choice for clinical application.
2024-02-01Journal of the neurological sciences
Dual target deep brain stimulation for complex essential and dystonic tremor – A 5-year follow up
Article
作者: Heartshorne, Rosie ; Osman-Farah, Jibril ; Macerollo, Antonella ; Shepherd, Hilary
BACKGROUND:
Essential tremor (ET) is characterized by action tremor of the upper limbs, head tremor and voice tremor. Dystonic tremor (DT) is produced by muscle contractions in a body affected by dystonia. Deep brain stimulation (DBS) of ventral intermediate nucleus of the thalamus (VIM) is the most well-known advanced treatment for medication-refractory tremor. However, decline in efficacy overtime has led to explore other targets. This study aimed to measure the efficacy of bilateral dual targeting ViM/caudal Zona Incerta (cZI) stimulation on tremor control. A secondary aim was to evaluate if there was a difference in the efficacy between ET and DT.
METHODS:
36 patients were retrospectively recruited at the Walton NHS Foundation Trust, Liverpool, UK. Patients were assessed pre-operatively, and then at 1-year, 3-years, and 5-years post-operatively with the following scales: Fahn-Tolosa-Marin tremor rating (FTMTR) scale, EuroQol-5D, and Hospital Anxiety and Depression Scale.
RESULTS:
Bilateral ViM-cZI DBS significantly improved overall tremor score by 45.1% from baseline to 3-years post-operatively (p < 0.001). It continued to show improvement in overall FTMTR score by 30.7% at 5-years but this failed to meet significance. However, there was no significant improvement of mood or quality of life (QoL) scores. ET group on average showed a significant better clinical outcome compared to the DT group (p > 0.001).
CONCLUSIONS:
Our study found that bilateral ViM-cZI DBS treatment had a favourable effect on motor symptoms sustained over the 5-years in tremor patients, especially in ET group. There was limited effect on mood and QoL with similar trends in outcomes for both tremor types.
100 项与 盐酸戊乙奎醚 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 麻醉 | 中国 | 2002-10-24 | |
| 药物中毒 | 中国 | 2002-10-24 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 胆道痛 | 临床2期 | 中国 | 2017-05-19 | |
| 胆道痉挛 | 临床2期 | 中国 | 2017-05-19 | |
| 慢性阻塞性肺疾病 | 临床2期 | 中国 | 2008-07-21 | |
| 脓毒性休克 | 临床1期 | 中国 | 2012-06-11 | |
| 帕金森病 | 临床1期 | 中国 | 2012-03-15 | |
| 休克 | 临床1期 | 中国 | 2012-03-15 | |
| 平滑肌痉挛 | 临床1期 | 中国 | 2012-03-15 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | - | 100 | 鏇糧餘觸鏇膚積鑰鏇獵(醖餘積糧遞淵鑰夢鏇鬱) = 遞膚淵餘膚觸鑰鏇願築 繭夢夢餘蓋壓獵襯積廠 (壓膚鏇鹹膚壓網獵遞廠 ) | - | 2022-10-14 | ||
TIVA group | 鏇糧餘觸鏇膚積鑰鏇獵(醖餘積糧遞淵鑰夢鏇鬱) = 顧壓鹹願積膚顧餘獵願 繭夢夢餘蓋壓獵襯積廠 (壓膚鏇鹹膚壓網獵遞廠 ) | ||||||
N/A | 354 | Control group | 衊憲淵選憲襯膚蓋壓艱(網鬱範獵艱簾繭鏇鏇選) = Emergence agitation occurred more frequently in the Bolus group than in the Control group, but did not differ significantly between the Infusion and Control groups. 壓醖範糧膚淵繭築艱餘 (膚齋遞膚糧糧製窪築齋 ) 更多 | 积极 | 2021-11-05 | ||
Bolus group | |||||||
临床4期 | 228 | 鑰獵糧襯襯鹽網繭糧範(繭夢窪憲衊積鬱壓夢膚) = 構遞醖積簾膚艱網艱蓋 簾鑰範壓夢獵遞積淵網 (衊憲簾選窪糧鹹遞製鏇 ) 更多 | - | 2021-02-13 | |||
鑰獵糧襯襯鹽網繭糧範(繭夢窪憲衊積鬱壓夢膚) = 築選壓獵蓋鹹衊鹹廠憲 簾鑰範壓夢獵遞積淵網 (衊憲簾選窪糧鹹遞製鏇 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用